Solitary solutions to an androgen-deprivation prostate cancer treatment model

被引：3

作者：

Telksnys, T. ^{[1
]}

Timofejeva, I. ^{[1
]}

Navickas, Z. ^{[1
]}

Marcinkevicius, R. ^{[2
]}

Mickevicius, R. ^{[3
]}

Ragulskis, M. ^{[1
]}

机构：

[1] Kaunas Univ Technol, Ctr Nonlinear Syst, Studentu 50-147, LT-51368 Kaunas, Lithuania

[2] Kaunas Univ Technol, Dept Software Engn, Studentu 50-415, LT-51368 Kaunas, Lithuania

[3] Lithuanian Univ Hlth Sci, Urol Clin, Eiveniu 2, LT-50009 Kaunas, Lithuania

来源：

MATHEMATICAL METHODS IN THE APPLIED SCIENCES | 2020年 / 43卷 / 07期

关键词：

androgen deprivation therapy; prostate cancer model; solitary solution; IDENTIFICATION; SYSTEMS;

D O I：

10.1002/mma.6168

中图分类号：

O29 [应用数学];

学科分类号：

070104 ;

摘要：

A model of androgen deprivation treatment for prostate cancer is considered in this paper. Bright/dark solitary solutions to the model are constructed using inverse balancing and generalized differential operator techniques. It is shown that solitary solutions correspond to biomedically relevant sets of model parameters. Dynamical properties of solitary solutions are analyzed in the phase plane. It is demonstrated that such solutions closely reflect the real-world phenomena observed during androgen deprivation treatment. Computational experiments are used to illustrate these effects.

引用

页码：3995 / 4006

页数：12

共 50 条

[31] Vascular responses to radiotherapy and androgen-deprivation therapy in experimental prostate cancer
Roe, Kathrine
Mikalsen, Lars T. G.
van der Kogel, Albert J.
Bussink, Johan
Lyng, Heidi
Ree, Anne H.
Marignol, Laure
Olsen, Dag R.
RADIATION ONCOLOGY, 2012, 7
[32] Androgen-deprivation therapy in prostate cancer: clinical evidence and future perspectives
Pinto, F.
Calarco, A.
Totaro, A.
Sacco, E.
Volpe, A.
Racioppi, M.
D'Addessi, A.
Bassi, P. F.
UROLOGIA JOURNAL, 2010, 77 (02) : 71 - 83
[33] Vascular responses to radiotherapy and androgen-deprivation therapy in experimental prostate cancer
Kathrine Røe
Lars TG Mikalsen
Albert J van der Kogel
Johan Bussink
Heidi Lyng
Anne H Ree
Laure Marignol
Dag R Olsen
Radiation Oncology, 7
[34] Is intermittent androgen-deprivation therapy beneficial for patients with advanced prostate cancer?
Wolff, Johannes M.
Abrahamsson, Per-Anders
Irani, Jacques
da Silva, Fernando Calais
BJU INTERNATIONAL, 2014, 114 (04) : 476 - 483
[35] Development of an androgen-deprivation induced and androgen suppressed human prostate cancer cell line
Lee, Soo Ok
Dutt, Smitha S.
Nadiminty, Nagalakshmi
Pinder, Elaine
Liao, Hongtao
Gao, Allen C.
PROSTATE, 2007, 67 (12): : 1293 - 1300
[36] A meta-analysis of cardiovascular events in intermittent androgen-deprivation therapy versus continuous androgen-deprivation therapy for prostate cancer patients
Jin, C.
Fan, Y.
Meng, Y.
Shen, C.
Wang, Y.
Hu, S.
Cui, C.
Xu, T.
Yu, W.
Jin, J.
PROSTATE CANCER AND PROSTATIC DISEASES, 2016, 19 (04) : 333 - 339
[37] Age and androgen-deprivation therapy on exercise outcomes in men with prostate cancer
Angela S. Alberga
Roanne J. Segal
Robert D. Reid
Chris G. Scott
Ronald J. Sigal
Farah Khandwala
James Jaffey
George A. Wells
Glen P. Kenny
Supportive Care in Cancer, 2012, 20 : 971 - 981
[38] Androgen-Deprivation Therapy in Prostate Cancer: A European Expert Panel Review
Schulman, Claude C.
Irani, Jacques
Morote, Juan
Schalken, Jack A.
Montorsi, Francesco
Chlosta, Piotr L.
Heidenreich, Axel
EUROPEAN UROLOGY SUPPLEMENTS, 2010, 9 (07) : 675 - 691
[39] Androgen-deprivation Therapy and Risk for Biliary Disease in Men with Prostate Cancer
Saylor, Philip J.
Smith, Matthew R.
O'Malley, A. James
Keating, Nancy L.
EUROPEAN UROLOGY, 2014, 65 (03) : 642 - 649
[40] Psychological Effects of Androgen-Deprivation Therapy on Men With Prostate Cancer and Their Partners
Donovan, Kristine A.
Walker, Lauren M.
Wassersug, Richard J.
Thompson, Lora M. A.
Robinson, John W.
CANCER, 2015, 121 (24) : 4286 - 4299

← 1 2 3 4 5 →